| Dr Kris Strohbehn, MD | |
|
1 Medical Center Dr, Dartmouth-hitchcock Medical Center, Lebanon, NH 03756-1000 | |
| (603) 653-9312 | |
| (603) 650-0902 |
| Full Name | Dr Kris Strohbehn |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 36 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023037538 | NPI | - | NPPES |
| 0RE5670 | Medicaid | VT | |
| 30200737 | Medicaid | NH |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Cheshire Medical Center | Keene, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.
Researchers at Princeton have developed a new chemical reaction that breaks the strongest bond in a molecule instead of the weakest, completely reversing the norm for reactions in which bonds are evenly split to form reactive intermediates.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.
New research conducted in the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health, reports that children with autism and gastrointestinal disturbances have high levels of a bacterium called Sutterella in their intestines.
At Pittcon 2014 Bruker announced a new sample automation system for the minispec mq and mq-one series, a new easy to use and cost-effective system that brings sample automation to routine Time-Domain (TD)-NMR applications. Its fast sample exchange of 10mm OD sample tubes delivers new levels of maximum throughput and thanks to automated and precise tempering times measurement reliability is improved, significantly boosting productivity of the minispec series.
› Verified 4 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.
Researchers at Princeton have developed a new chemical reaction that breaks the strongest bond in a molecule instead of the weakest, completely reversing the norm for reactions in which bonds are evenly split to form reactive intermediates.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.
New research conducted in the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health, reports that children with autism and gastrointestinal disturbances have high levels of a bacterium called Sutterella in their intestines.
At Pittcon 2014 Bruker announced a new sample automation system for the minispec mq and mq-one series, a new easy to use and cost-effective system that brings sample automation to routine Time-Domain (TD)-NMR applications. Its fast sample exchange of 10mm OD sample tubes delivers new levels of maximum throughput and thanks to automated and precise tempering times measurement reliability is improved, significantly boosting productivity of the minispec series.
› Verified 4 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.
Researchers at Princeton have developed a new chemical reaction that breaks the strongest bond in a molecule instead of the weakest, completely reversing the norm for reactions in which bonds are evenly split to form reactive intermediates.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.
New research conducted in the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health, reports that children with autism and gastrointestinal disturbances have high levels of a bacterium called Sutterella in their intestines.
At Pittcon 2014 Bruker announced a new sample automation system for the minispec mq and mq-one series, a new easy to use and cost-effective system that brings sample automation to routine Time-Domain (TD)-NMR applications. Its fast sample exchange of 10mm OD sample tubes delivers new levels of maximum throughput and thanks to automated and precise tempering times measurement reliability is improved, significantly boosting productivity of the minispec series.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kris Strohbehn, MD 1 Medical Center Dr, Dartmouth-hitchcock Medical Center, Lebanon, NH 03756-1000 Ph: (603) 653-9312 | Dr Kris Strohbehn, MD 1 Medical Center Dr, Dartmouth-hitchcock Medical Center, Lebanon, NH 03756-1000 Ph: (603) 653-9312 |
News Archive
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.
Researchers at Princeton have developed a new chemical reaction that breaks the strongest bond in a molecule instead of the weakest, completely reversing the norm for reactions in which bonds are evenly split to form reactive intermediates.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.
New research conducted in the Center for Infection and Immunity (CII) at Columbia University's Mailman School of Public Health, reports that children with autism and gastrointestinal disturbances have high levels of a bacterium called Sutterella in their intestines.
At Pittcon 2014 Bruker announced a new sample automation system for the minispec mq and mq-one series, a new easy to use and cost-effective system that brings sample automation to routine Time-Domain (TD)-NMR applications. Its fast sample exchange of 10mm OD sample tubes delivers new levels of maximum throughput and thanks to automated and precise tempering times measurement reliability is improved, significantly boosting productivity of the minispec series.
› Verified 4 days ago
Kelsey Kredentser, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Suzanne Davey Shipman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 141 Mascoma St, Lebanon, NH 03766 Phone: 603-448-3996 Fax: 603-448-6863 | |
Cecelia V Brelsford, APRN Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-9300 | |
Ann J. Davis, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-9384 | |
Amy E Paris, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Obstetrics & Gynecology, Lebanon, NH 03756 Phone: 603-653-9300 | |
Ariel Kredentser, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 |